It's a good question. I guess the more one trials and gathers...

It's a good question. I guess the more one trials and gathers data the answer shall be revealed. But from all accounts it would appear higher doses are believed to create greater immune responses within cancer patients, therein efficacy. The cancers linked to success thus far are deep within the patients body, often referred to as "difficult to locate tumours', hence the exuberance at initial progress in the Vaxinia (MAST) Trial.

The data is starting to gather, revealing the pieces in the puzzle sought after by LC. Time is sure to reveal which dose was most successful with each specific cancer indication. Until then we can only marvel at the results thus far. Staggering to say the least when one considers the high rate of disease stabilisation, taking all things into account.

WMHB